GAAP and non-GAAP earnings per share include the net impact of Acquired IPRD & licensing income due to ($0.10) incurred in Q1 and an additional ($0.11) due to the buyout of a future royalty obligation related to mavacamten that occurred in April 2022. Phase 3 CheckMate -76K trial evaluating Opdivo as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo at a pre-specified interim analysis. GAAP and non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income which increased by $0.02 per share in the third quarter of 2022 compared to a reduction of ($0.09) per share in the third quarter of 2021. Investors and the public can also access the live webcast by dialing in the U.S. toll free 866-409-1555 or international +1 786-789-4797, confirmation code: 5513095. Revenues for in-line products in the first quarter were $8.3 billion compared to $7.7 billion in the prior year period, representing an increase of 8%. Interim results from the Phase 3 True North open-label extension trial demonstrated that the percentage of patients achieving clinical remission, clinical response, endoscopic improvement and corticosteroid-free remission was maintained through Week 142 for patients with moderately to severely active ulcerative colitis who were treated with Zeposia. * GAAP and non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income which increased by $0.02 per share in the third quarter of 2022 compared to a reduction of ($0.09) per share in the third quarter of 2021. The sBLA is based on results from the Phase 3 TRANSFORM trial. (c) Includes amortization of purchase price adjustments to Celgene debt. Prior period results have been revised for comparability. In the first quarter of 2022, GAAP and non-GAAP earnings per share include a net impact of ($0.10) per share due to Acquired IPRD charges that were partially offset by licensing income. September 30, 2021, % Change from To learn more about our priorities and goals, please visit our latest ESG report. ET on October 26 through 11:30 a.m. In addition to the items discussed above, the results in the current period included the impact of lower weighted-average common shares outstanding. Hematology Development, Bristol Myers Squibb. A discussion of the non-GAAP financial measures is included under the Use of Non-GAAP Financial Information section. https://lnkd.in/e5EBRBd. Ireland is home to External manufacturing's global headquarters, the business unit responsible for the management of manufacturing contract operations (CMO's) and ensuring reliable supply of product to . International revenues decreased 24% to $3.3 billion in the quarter. F/X Impact), Total In-Line Products and New Product Portfolio Revenue. New product portfolio revenues grew to $553 million compared to $344 million in the prior year period, representing growth of 61% driven by the launch of Opdualag and higher demand for Abecma and Reblozyl. A discussion of the non-GAAP financial measures is included under the Use of Non-GAAP Financial Information section. Bristol-Myers Squibb Company, which has a market valuation of $169.55 billion, is expected to release its quarterly earnings report Feb 02, 2023. The company reported net earnings attributable to Bristol Myers Squibb of $1.6 billion, or $0.75 per share, in the third quarter, compared to $1.5 billion, or $0.69 per share, for the same period a year ago. To be directly connected to the conference call, enter your information here; the link will be active 15 minutes prior to the scheduled start time of the call, and does not require a dial-in number or operator assistance to be connected. We may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. (a) Includes over-the-counter (OTC) products, royalty revenue and mature products. Acquired IPRD in the current quarter is related to the GentiBio licensing transaction. Bristol Myers Squibb has been in operation in Ireland since 1964, employing over 650 people across a range of activities and business units. Ten years of annual and quarterly financial statements and annual report data for Bristol Myers Squibb (BMY). Beginning with the first quarter of 2022, significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights are no longer excluded from our non-GAAP financial measures. We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. BMS' top-line revenue in 2021 was $46.39 billion, an improvement of 9.1 percent over the previous year. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. % Change from
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021, (Unaudited, dollars and shares in millions except per share data), Amortization of acquired intangible assets. New product portfolio revenues grew to $553 million compared to $344 million in the prior year period, representing growth of 61% driven by the launch of, In August, the company announced that it had completed its acquisition of Turning Point in an all-cash transaction. (b) Includes amortization of purchase price adjustments to Celgene debt. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. "We are pleased with the positive results of the COMMANDS study and . Our strong results reflect growth of our in-line and new product portfolios, said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. As a leading biopharma company, we understand our responsibility extends well beyond the discovery, development, and delivery of innovative medicines. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. To learn more, please visit our latest Global Inclusion & Diversity Report. International revenues were $250 million compared to $1.0 billion in the prior year period, representing a decrease of 76% driven by lower demand as a result of generic erosion and to a lesser extent, foreign exchange impacts. Salaries posted anonymously by Bristol Myers Squibb employees in Clay, NY. Our teams continue to progress our pipeline and achieve significant regulatory and clinical milestones, including the approval of Sotyktu, a first-in-class, TYK2 inhibitor, to treat moderate to severe plaque psoriasis. The European Commission (EC) approved the fixed-dose combination of Opdualag for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumor cell PD-L1 expression < 1%. Reports Third Quarter Revenues of $11.2 Billion, Delivers Strong Revenue Growth of 8% from In-Line Products and New Product Portfolio; or 13% When Adjusted for Foreign Exchange, Posts Third Quarter Earnings Per Share of $0.75 and Non-GAAP EPS of $1.99; Includes Net Increase of $0.02 Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges and Licensing Income, Bolsters New Product Portfolio with FDA Approval for SotyktuTM, a First-in-Class TYK2 inhibitor for Adults with Moderate-to-Severe Plaque Psoriasis, Continues to Progress Product Pipeline with Significant Regulatory and Clinical Milestones, Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio, Adjusts 2022 GAAP EPS Guidance; Reaffirms Non-GAAP EPS Guidance. October 31, 2022 at 06:59 AM EDT. NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2022, which reflect strong in-line and new product portfolio growth. Forward-looking statements contained in this document should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary statement and risk factors discussion in the company's most recent annual report on Form 10-K, quarterly reports on Form 10-Q and . Ireland is home to External manufacturing's global headquarters, the business unit responsible for the management of manufacturing contract operations (CMO's) and ensuring reliable supply of product to . Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com., Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, Subscribe to Press Release Email Alerts>, Read Acquisition FAQs for Celgene Shareholders>, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. Beginning with the first quarter of 2022, significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights are no longer excluded from non-GAAP results. NEW YORK--(BUSINESS WIRE)--
The FDA approved Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Findings from clinical, patient-reported outcomes and real-world . Actual results may differ from those indicated as a result of various important factors, including those discussed in the company's most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS, Net Earnings Attributable to BMS used for Diluted EPS Calculation, Weighted-Average Common Shares Outstanding - Diluted. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. March 31, 2021
In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. Presiding: Giovanni Caforio, M.D., Board Chair and Chief Executive Officer. November 09, 2022. (b) Recent LOE Products includes products with significant expected decline in revenue from a prior reporting period as a result of a loss of exclusivity. No forward-looking statement can be guaranteed. The FDA approved Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. No forward-looking statement can be guaranteed, including that the companys future clinical studies will support the data described in this release, product candidates will receive necessary clinical and manufacturing regulatory approvals, pipeline products will prove to be commercially successful, clinical and manufacturing regulatory approvals will be sought or obtained within currently expected timeframes or contractual milestones will be achieved. All comparisons are made versus the same period in 2021 unless otherwise stated. The 2022 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified and impact of future Acquired IPRD charges. Bristol Myers Squibb will host a conference call tomorrow, Wednesday, October 26, 2022 at 8 a.m. As a leading biopharma company, we understand our responsibility extends well beyond the discovery, development, and delivery of innovative medicines. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com., Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the companys financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the companys baseline performance, supplement or enhance management, analysts and investors overall understanding of the companys underlying financial performance and trends and facilitate comparisons among current, past and future periods. "Our teams continue to progress our pipeline and achieve significant regulatory and clinical milestones, including the approval of Sotyktu, a first-in-class, TYK2 inhibitor, to treat moderate to severe plaque psoriasis. ** Includes over-the-counter (OTC) products, royalty revenue and other mature products. Bristol Myers Squibb 3y Report this post Today our CEO, Giovanni Caforio, becomes chairman of the PhRMA board of directors and will play a leading role in the global dialogue on healthcare, patient access and delivering innovative medicines to treat the world's most challenging diseases. Findings from clinical, patient-reported outcomes and real-world studies will be . We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. A replay of the webcast will be available on http://investor.bms.com approximately three hours after the conference call concludes. (a) Includes over-the-counter (OTC) products, royalty revenue and mature products. Phase 2 AXIOMATIC-SSP trial showed that milvexian had an approximate 30% relative risk reduction in recurrent symptomatic ischemic strokes (accepted regulatory endpoint) and favorable safety profile in three arms compared to placebo when used in combination with background dual antiplatelet therapy in patients with an acute non-cardioembolic ischemic stroke or transient ischemic attack. madurai to coimbatore car travel time logistic regression max iterations used hot mix plant for sale near budapest. This marks the first immunotherapy-based treatment approved in this setting. A replay of the conference call will be available beginning at 11:30 a.m. In addition to the items discussed above, the results include the impact of fair value adjustments on equity investments and contingent value rights in both periods. (c) Includes Puerto Rico. Sometimes they bristol myers squibb diabetes drugs ask for more things from what is estimated average glucose themselves, but they don t blood sugar medication names have the right to enjoy these more things, and they don t have the the blooding summary right to bear the responsibility for these more things. This earnings release and the related attachments (as well as the oral statements made with respect to information contained in this release and the attachments) contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, statements relating to goals, plans and projections regarding the companys current and projected financial position, results of operations, market position, product development, share repurchase program and business strategy. Quarter Ended
When adjusted for foreign exchange impacts, international revenues decreased 14%, primarily due to lower demand of Revlimid as a result of generic erosion, partially offset by in-line products (primarily Opdivo) and our new product portfolio. The FDA accepted for priority review the supplemental Biologics License Application (sBLA) to expand its current indication to include earlier use of Breyanzi for the treatment of adults with relapsed or refractory large B-cell lymphoma after failure of first-line therapy. Acquired IPRD decreased from $271 million in the same period a year ago to $30 million in the current quarter. For purposes of comparability, the non-GAAP financial results for the first quarter of 2021 have been updated to reflect this change. ET on November 9, 2022, by dialing in the U.S. toll free 800-770-2030 or international +1 647-362-9199, confirmation code: 24168. Most Recent Quarter Revenue $11.9B (Q2'2022) Peak Revenue $46.4B (2021) Number of Employees 30,000 Revenue / Employee $1.5M Jobs In Pharmaceutical and Fortune 500 Location Job Title Distance Job Type Job Level Education Date Posted Beginning with the first quarter of 2022, significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights are no longer excluded from non-GAAP results. Dial-in participants can register for the conference call here and once registration is complete, will not require operator assistance to connect. Bristol-Myers Squibb annual revenue for 2020 was $42.5B, a 62.62% growth from 2019. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. A replay of the conference call will be available beginning at 11:30 a.m. EDT on April 29 through 11:30 a.m. EDT on May 13, 2022, by dialing in the U.S. toll free 888-203-1112 or international +1 719-457-0820, confirmation code: 5513095. For purposes of comparability, the non-GAAP financial measures for the three months ended March 31, 2021 have been updated to reflect this change. NEW YORK, (BUSINESS WIRE) -- Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2022, which reflect strong in-line and new. The website may also contain certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. Company executives will review financial results and address inquiries from. Cautionary Statement Regarding Forward-Looking Statements. The company reported net earnings attributable to Bristol Myers Squibb of $1.6 billion, or $0.75 per share, in the third quarter, compared to $1.5 billion, or $0.69 per share, for the same period . (Unaudited, dollars and shares in millions except per share data), Amortization of acquired intangible assets. Research and development expenses decreased 19% to $2.4 billion in the quarter, primarily due to an in-process research and development (IPRD) impairment charge in 2021, timing of clinical development spend and foreign exchange impacts, partially offset by cash settlement of Turning Point unvested stock awards. This earnings release and the accompanying tables also provide certain revenues and expenses as well as non-GAAP measures excluding the impact of foreign exchange. Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at the AHA Annual Scientific Sessions 2022 include: . * GAAP and non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income which increased by $0.02 per share in the third quarter of 2022 compared to a reduction of ($0.09) per share in the third quarter of 2021. Our nine new product launches over the last three years including three first-in-class launches this year, combined with progress in our robust and diverse product pipeline, have built a strong foundation for our company. $ amounts in millions, except per share amounts. The company reported non-GAAP net earnings attributable to Bristol Myers Squibb of $4.2 billion, or $1.96 per share, in the first quarter, compared to non-GAAP net earnings of $4.0 billion, or $1.74 per share, for the same period a year ago. Weighted-Average Common Shares Outstanding: (a) Excludes amortization of acquired intangible assets. NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2022, which reflect robust in-line product growth, increased adoption of new product portfolio and strong commercial execution. 5 min read In this article we are going to estimate the intrinsic value of Bristol-Myers Squibb Company ( NYSE:BMY) by taking the expected future. On a non-GAAP basis, marketing, selling and administrative expenses increased 4% to $1.9 billion primarily due to higher investments to support new product launches, partially offset by foreign exchange impacts. "I am very pleased with the continued strong demand for our in-line products and new product portfolio, resulting in solid top and bottom-line growth . Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in the press release that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. The management proposal on the advisory vote to approve the compensation of our named executive officers was approved by a vote of 1,419,400,241 shares in favor, with 125,669,113 shares against, 7,303,247 shares abstaining and 279,523,156 broker non-votes. Inventory purchase price accounting adjustments. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the companys most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. September 30, 2021 Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date. In addition, the financial guidance provided in this release relies on assumptions about the duration and severity of the COVID-19 pandemic, timing of the return to a more stable business environment, patient and physician behaviors, buying patterns and clinical trial activities, which may prove to be incorrect. The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the companys financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the companys baseline performance, supplement or enhance management, analysts and investors overall understanding of the companys underlying financial performance and trends and facilitate comparisons among current, past and future periods. In addition, non-GAAP gross margin, which is gross profit excluding certain specified items, as a percentage of revenues, non-GAAP operating expenses, which is marketing, selling and administrative and research and development expenses excluding certain specified items, non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expense excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results. Combined with our financial strength and talented employees, Bristol Myers Squibb is well positioned for growth and to advance new medicines for patients.". Opdivo is the first immunotherapy approved for these patients. In oncology, hematology, immunology and cardiovascular disease - and one of the most diverse and promising pipelines in the industry - each of our passionate colleagues contribute to innovations that drive meaningful change. The company reported non-GAAP net earnings attributable to Bristol Myers Squibb of $4.3 billion, or $1.99 per share, in the third quarter, compared to non-GAAP net earnings of $4.3 billion, or $1.93 per share, for the same period a year ago. Bristol Myers Squibb revenue for the twelve months ending September 30, 2022 was $46.738B, a 2.79% increase year-over-year. FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021. Shares of Bristol Myers Squibb BMY, -0.30% were up 1.2% in premarket trading on Wednesday, the day after the company shared better-than-expected results for the third quarter of the year. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Based upon subsequent results from pre-planned analyses of two late-stage clinical studies in renal cell carcinomaand bladder cancer, coupled with the results of the PIVOT IO-001 trial in metastatic melanoma, BMS and Nektar have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. March 31, 2021, % Change from
F/X Impact), Total In-Line Products and New Product Portfolio Revenue. To the extent we have quantified the impact of significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights, we may update this information from time to time on our website, www.bms.com, in the Investors section. Phase 3 CheckMate -76K trial evaluating Opdivo as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo at a pre-specified interim analysis. Bristol-Myers Squibb Co (BSP:BMYB34) ROE % Adjusted to Book Value as of today (November 08, 2022) is 4.14%. In 2022, Eliquis passed Revlimid to become Bristol Myers' top-selling product. The EC also approved Opdivoin combination with fluoropyrimidine and platinum-based chemotherapy for the same indication. Findings from clinical, patient-reported outcomes and . 3 Inclusive of net impact of ($0.21) of acquired IPRD and licensing income. No forward-looking statement can be guaranteed, including that the companys future clinical studies will support the data described in this release, product candidates will receive necessary clinical and manufacturing regulatory approvals, pipeline products will prove to be commercially successful, clinical and manufacturing regulatory approvals will be sought or obtained within currently expected timeframes, or that contractual milestones will be achieved.